D. Boral Capital Reiterates “Buy” Rating for OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $20.00 target price on the stock.

OS Therapies Stock Performance

Shares of OS Therapies stock opened at $2.25 on Friday. The stock has a market capitalization of $71.20 million and a PE ratio of -2.85. OS Therapies has a 52-week low of $1.12 and a 52-week high of $7.00. The company has a 50-day simple moving average of $1.96 and a two-hundred day simple moving average of $1.77.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bridgeway Capital Management LLC purchased a new position in OS Therapies in the second quarter worth about $47,000. XTX Topco Ltd purchased a new position in OS Therapies in the second quarter worth about $63,000. Finally, CM Management LLC raised its holdings in OS Therapies by 172.6% in the first quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $462,000 after buying an additional 189,956 shares during the last quarter.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.